Lurasidone wins for a composite baker with prediabetes and a pre-dawn shift, while MN663's Unit 2 comparison keeps a full record of what quetiapine would have offered. Searches like "mn 663 unit 2 assignment example", "mn663 unit 2 sample" and "mn663 unit 2 example" land here.
Quetiapine or Lurasidone for Bipolar Depression in a Bakery Shift Lead Who Wakes at 3:30 a.m.: A Medication Comparison
[Student Name]
Purdue University Global
MN663: PMHNP Diagnosis and Management Across the Lifespan I
Unit 2 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. Doses are omitted or bracketed; nothing here is a prescribing instruction.
The Patient and the Decision Rule
A composite 27-year-old woman with bipolar I disorder is in a major depressive episode, her third, with low mood, loss of interest, hypersomnia on days off and poor concentration. She has no current mixed features. She is a shift lead at a commercial bakery and must be alert at 3:30 a.m. five days a week. Her body mass index is 29, her hemoglobin A1c is 6.1 percent, and her mother has type 2 diabetes. She took lithium in the past and stopped it because of tremor and thirst. She is not pregnant and uses an intrauterine device.
Decision rule, stated before either drug is weighed: for this patient, metabolic risk and morning alertness outweigh a modest difference in the breadth of evidence. Stating the rule first matters because each drug wins on some dimension. Without a rule, a comparison can drift toward whichever advantage the writer happens to discuss last. The rule comes from her own priorities as well as her risks: she said her biggest fear about medication was "gaining weight like my mom" and her second was "being too foggy to run the line."
Comparison Table
Indication. Quetiapine: FDA-approved for depressive episodes of bipolar I and bipolar II disorder. Lurasidone: FDA-approved in 2013 for depressive episodes of bipolar I disorder, alone or with lithium or valproate.
Efficacy evidence. Quetiapine: placebo-controlled trials, including the BOLDER studies, showed improvement in bipolar depression in both bipolar I and II (Calabrese et al., 2005). Lurasidone: a six-week placebo-controlled trial in bipolar I depression showed improvement in depressive symptoms (Loebel et al., 2014).
Weight and glucose. Quetiapine: associated with clinically meaningful weight gain and adverse effects on glucose and lipids. Lurasidone: smaller metabolic effects in trials.
Sedation. Quetiapine: marked sedation, common and often dose-limiting. Lurasidone: sedation less prominent; somnolence occurs in some patients.
Other common adverse effects. Quetiapine: dry mouth, dizziness, orthostatic hypotension. Lurasidone: akathisia and nausea.
Interactions and administration. Quetiapine: metabolized by CYP3A4; usually once daily at bedtime for bipolar depression. Lurasidone: must be taken with food, at least 350 calories; contraindicated with strong CYP3A4 inhibitors and inducers.
Boxed warnings, both drugs: increased mortality in older adults with dementia-related psychosis, and increased risk of suicidal thoughts and behaviors in children, adolescents and young adults.
Metabolic Burden Comes First
With an A1c of 6.1 percent, a body mass index of 29 and a mother with type 2 diabetes, weight gain and worsening glucose are the harms with the longest consequences for her, which puts metabolic burden first among the rows. Quetiapine's association with weight gain and glucose changes makes it a poor fit for a woman already at the threshold of diabetes, and bipolar disorder often requires years of treatment. Lurasidone's smaller metabolic effects in trials are the main reason it is preferred, although monitoring of weight, glucose and lipids is required with either drug.
Sedation Comes Second
A drug that leaves her groggy at 3:30 a.m. would affect her safety at work, where she operates ovens and mixers, and would likely be stopped by her rather than by a prescriber. Quetiapine is usually taken at bedtime and often causes next-morning sedation, especially early in treatment. Lurasidone is less sedating, which fits her schedule better, although some patients do report somnolence and she would be asked about morning alertness at each visit.
Efficacy Comes Third
Quetiapine's evidence is broader. It has more placebo-controlled trials in bipolar depression and covers bipolar II as well as bipolar I, and the paper concedes that. For her bipolar I depression, both drugs have trial evidence of benefit over placebo, and the difference in breadth does not outweigh the metabolic and sedation differences under the decision rule.
The Price of the Choice
Lurasidone has costs of its own. It must be taken with a meal of at least 350 calories, which will require her to eat a real breakfast or evening meal when she takes it, and her irregular shift schedule makes that harder. Akathisia, an uncomfortable inner restlessness, is its most common troublesome effect and can be mistaken for anxiety or agitation; she will be told what it feels like and asked about it at each visit. It cannot be combined with strong CYP3A4 inhibitors, such as clarithromycin, or inducers, such as rifampin, so any new prescription must be checked. And it is usually more expensive than generic quetiapine, which her insurance coverage must be checked for.
Other Options Set Aside
Two other approaches were considered briefly. Restarting lithium has strong long-term evidence in bipolar disorder, but she stopped it because of tremor and thirst and does not want to try it again now; that preference is respected, and lithium remains an option to revisit later. An antidepressant alone is avoided in bipolar I disorder because of limited evidence of benefit and concern about switching into mania. Cariprazine, another agent approved for bipolar I depression, would be a reasonable alternative if lurasidone failed, but it was not part of this comparison.
Monitoring Plan
Whichever drug is used, second-generation antipsychotics call for metabolic monitoring. Following the consensus recommendations for antipsychotic monitoring, she will have weight measured at baseline and at weeks 4, 8 and 12, then quarterly; fasting glucose or A1c and blood pressure at baseline, week 12 and yearly; and a fasting lipid panel at baseline and week 12 (American Diabetes Association et al., 2004). Because her A1c is already 6.1 percent, the plan checks it at week 12 and again at six months rather than waiting a year. Akathisia and morning alertness will be asked about at every visit, and suicidal thoughts will be assessed at every visit given the boxed warning and her age.
When Quetiapine Would Return to First Choice
Quetiapine would become the better option if lurasidone produced intolerable akathisia or nausea, if she needed a medication for sleep during a period of severe insomnia and was not working early shifts, if cost made lurasidone unavailable, or if a future episode showed features of bipolar II depression for which quetiapine has stronger evidence. Each of those circumstances would change the balance of the rows above, and the decision would be reviewed with her at that point rather than made for her.
References
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601. https://doi.org/10.2337/diacare.27.2.596
Calabrese, J. R., Keck, P. E., Jr., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., & BOLDER Study Group. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry, 162(7), 1351-1360. https://doi.org/10.1176/appi.ajp.162.7.1351
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014). Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. American Journal of Psychiatry, 171(2), 160-168. https://doi.org/10.1176/appi.ajp.2013.13070984
How this MN663 Unit 2 example is structured
The comparison opens by stating its decision rule before either drug is named: for this patient, metabolic risk and morning function outweigh a modest difference in evidence. The table follows, every cell cited. Argument paragraphs then take the rows in order of weight for her. Metabolic burden comes first, because her A1c and a mother with type 2 diabetes make weight gain the harm with the longest tail. Sedation comes second, since a drug that leaves her groggy before dawn would likely be stopped by her rather than by a prescriber. Efficacy comes third and is handled honestly: quetiapine's evidence is broader, and the paper concedes it. The practical demands of lurasidone, food and interaction limits, close the argument as the price of the choice. Quetiapine's route back to first choice, the circumstances that would restore it, fills the closing paragraph.
Get an MN663 Unit 2 example written to your instructions
Which two agents does your MN663 section's Unit 2 prompt name, or is the pair left open? Say which, and include the case and rubric. Expect a decision rule stated before either drug, a cited cell in every row of the table, and the circumstances that would reverse the choice, all in a free first comparison ready within 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN663 Unit 2 questions, answered
Does the comparison have to pick one agent?
Almost always. A comparison that ends in balance has described two drugs rather than compared them. If the case genuinely supports either, choose the one you would start, give the deciding reason, and say what finding would send you to the other. That conditional ending shows judgment, which is what the assignment exists to assess.
How much trial data belongs in the table?
Enough to show where each drug's evidence comes from: the registration trials for the indication in question, their length and their comparator. Effect sizes help if the prompt asks for them. Pages of trial detail crowd out the argument, and evidence from a different phase of illness, mania instead of depression, should be flagged or left out.
Should the comparison mention cost and insurance coverage?
Briefly, when the case raises it or when one agent is far more expensive. A plan the patient cannot fill is not a working plan, and graders in management courses tend to credit the recognition. Keep it to a sentence or two unless the prompt makes access a central question, and avoid quoting prices that change by plan and pharmacy.